Program
equecabtagene autoleucel
Also written as “Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)”, “Equecabtagene Autoleucel Injection” and “Equecabtagene Autoleucel Injection (Eque-cel)”.
Its studies are mostly in Multiple Myeloma · Muscular Diseases, led by Nanjing IASO Biotechnology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nanjing IASO Biotechnology | 54 open or running | phase 3since May 30, 2024 | Sep 22, 2021 | Aug 2027phase 3 · NCT06464991 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 22, 2021First study: phase 2 study in Multiple MyelomaFirst studyNCT05066646 · 132 enrolled · China
- Nov 21, 2021Phase 1 study in Multiple MyelomaNCT05181501 · 20 planned · China
- Dec 29, 2022Phase 1 study in Multiple MyelomaNCT05698303 · 12 planned · United States
- May 30, 2024Phase 3 study in Multiple MyelomaNCT06464991 · 260 enrolled · China, Japan
- Aug 3, 2026Phase 2 study in Refractory Immune-mediated Necrotizing MyopathyNCT07752264 · 27 planned · China
Ahead
- Aug 2027Primary completion: phase 3 study in Multiple MyelomaNCT06464991
- Aug 15, 2030Primary completion: phase 2 study in Refractory Immune-mediated Necrotizing MyopathyNCT07752264
TargetBeta
“A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) with a fully human single chain variable fragment (scFv) targeting the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor”NCIt, by rule
Other programs on TNFRSF17
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elranatamabrule | Pfizer | phase 4 | 15 |
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| belantamab mafodotinrule | GlaxoSmithKline | phase 3 | 25 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| anitocabtagene autoleucelrule | Gilead Sciences | phase 3 | 6 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| Evarucabgene Autoleucelrule | nexcella-inc | phase 3 | 2 |
| Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytesrule | cartesian-therapeutics | phase 2 | 6 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07752264Refractory Immune-mediated Necrotizing Myopathy · China | 2 | Not yet recruiting | Aug 15, 2030 | 27 |
| NCT06464991Multiple Myeloma · China, Japan | 3 | Active, not recruiting | Aug 2027 | 260 |
| NCT05698303Multiple Myeloma · United States | 1 | Not yet recruiting | May 20, 2024 | 12 |
| NCT05181501Multiple Myeloma · China | 1 | Not yet recruiting | Apr 2024 | 20 |
| NCT05066646Multiple Myeloma · China | 2 | UNKNOWN | Oct 2022 | 132 |
How it is read
Names in the registry
- “Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)”, 2 entries
- “Equecabtagene Autoleucel Injection”, 1 entry
- “Equecabtagene Autoleucel Injection (Eque-cel)”, 1 entry
- “CT103A”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 4 studies
- Muscular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.